文献速递妇产影像

无创产前筛查作为双胎妊娠21三体一线筛查策略的表现

Non-invasive cell-free DNA prenatal screening for trisomy 21 as part of primary screening strategy in twin pregnancy.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-04-30

这项回顾性队列研究纳入1885例双胎妊娠,以母血游离DNA无创产前筛查作为一线筛查策略,评估其对21三体的筛查性能。结果显示灵敏度为100%(95%CI 54.1-100%),假阳性率为0.23%(95%CI 0.06-0.59%)。初次检测失败率为4.6%,其中4.0%因胎儿分数不足;重新采血后总体失败率降至2.8%。母亲体重指数、筛查时孕龄及绒毛膜性是失败的相关因素。

要点

  • 双胎妊娠中以cfDNA无创产前筛查作为一线策略,对21三体灵敏度100%,假阳性率极低(0.23%)。
  • 初次检测失败率4.6%,主要因胎儿分数不足(4.0%);重新采血可使65.4%失败者获得成功结果,总体失败率降至2.8%。
  • 母亲BMI、筛查时孕龄及绒毛膜性与检测失败风险显著相关,阅片/报告时需关注这些因素。

局限性

  • 回顾性队列设计可能存在选择偏倚和信息偏倚。
  • 21三体确诊病例仅6例,灵敏度置信区间较宽(54.1-100%)。
  • 研究未报告其他染色体异常或非整倍体的筛查性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The performance of non-invasive prenatal screening using cell-free DNA testing of maternal blood in twin pregnancy is underevaluated, while serum marker-based strategies yield poor results. This study aimed to assess the performance of non-invasive prenatal screening for trisomy 21 in twin pregnancy as a first-tier test. Secondary objectives were to assess its failure rate and factors associated with failure.

METHODS: This retrospective cohort study included twin pregnancies in which non-invasive prenatal screening using cell-free DNA was performed as the primary screening strategy between May 2017 and October 2019. We used the NIPT VeriSeq® test for in-vitro diagnosis and set a fetal fraction cut-off of 4% for monochorionic pregnancies and 8% for dichorionic ones. Clinical data and pregnancy outcome were collected from physicians or midwives via a questionnaire or were retrieved directly on-site. We calculated the performance of non-invasive cell-free DNA screening for trisomy 21, analyzed its failure rate and assessed potentially associated factors.

RESULTS: Among 1885 twin pregnancies with follow-up, there were six (0.32%) confirmed cases of trisomy 21. The sensitivity of non-invasive prenatal screening for trisomy 21 was 100% (95% CI, 54.1-100%) and the false-positive rate was 0.23% (95% CI, 0.06-0.59%). The primary failure rate was 4.6%, with 4.0% being due to insufficient fetal fraction. A successful result was obtained for 65.4% of women who underwent a new blood draw, reducing the overall failure rate to 2.8%. Maternal body mass index, gestational age at screening as well as chorionicity were significantly associated with the risk of failure.

CONCLUSION: This study provides further evidence of the high performance, at an extremely low false-positive rate, of non-invasive prenatal screening in twins as part of a primary screening strategy for trisomy 21. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Claudel N, Barrois M, Vivanti AJ, et al. Non-invasive cell-free DNA prenatal screening for trisomy 21 as part of primary screening strategy in twin pregnancy. Ultrasound Obstet Gynecol. 2024. PMID: 37470702. doi:10.1002/uog.26311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。